Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | JiSook Kim, InHwan Bae, JaeYul Choi, MinJeong Kim, JooYun Byun, MiJin Moon, EunYoung Lee, Yu-Yon Kim, Hyun Jeong Kang, Eunyoung Kim, SunYoung Jung, YoungGil Ahn, YoungHoon Kim, Kwee Hyun Suh | ||||||||||||
Title | HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia | ||||||||||||
|
|||||||||||||
URL | https://cancerres.aacrjournals.org/content/79/13_Supplement/1293 | ||||||||||||
Abstract Text | Cancer Res 2019;79(13 Suppl):Abstract nr 1293 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Tuspetinib | Tuspetinib | 4 | 1 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tuspetinib | HM-43239|HM 43239|HM43239 | FLT3 Inhibitor 69 | Tuspetinib (HM43239) inhibits both wild-type and mutant FLT3, resulting in decreased activation of downstream signaling, and potentially leading to increased apoptosis and decreased proliferation of tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins FLT3 F691L | hematologic cancer | predicted - sensitive | Tuspetinib | Preclinical | Actionable | In a preclinical study, Tuspetinib (HM43239) treatment inhibited transformed cells expressing FLT3 ITD and F691L in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). | detail... |
FLT3 exon 14 ins FLT3 D835Y | hematologic cancer | predicted - sensitive | Tuspetinib | Preclinical | Actionable | In a preclinical study, Tuspetinib (HM43239) treatment inhibited transformed cells expressing FLT3 ITD and D835Y in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). | detail... |